Chen Qian, Wang Shi-Yang, Chen Yue, Yang Ming, Li Kai, Peng Zi-Yang, Xu Chong-Wen, Yao Xiao-Bao, Li Hong-Hui, Zhao Qian, Cao Yu-Dan, Bai Yan-Xia, Li Xiang
Department of Otorhinolaryngology Head and Neck Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Center for Gut Microbiome Research, Med-X Institute Centre, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Front Oncol. 2024 Jun 10;14:1399047. doi: 10.3389/fonc.2024.1399047. eCollection 2024.
The prognostic value of an effective biomarker, pan-immune-inflammation value (PIV), for head and neck squamous cell carcinoma (HNSCC) patients after radical surgery or chemoradiotherapy has not been well explored. This study aimed to construct and validate nomograms based on PIV to predict survival outcomes of HNSCC patients.
A total of 161 HNSCC patients who underwent radical surgery were enrolled retrospectively for development cohort. The cutoff of PIV was determined using the maximally selected rank statistics method. Multivariable Cox regression and least absolute shrinkage and selection operator (LASSO) regression analyses were performed to develop two nomograms (Model A and Model B) that predict disease-free survival (DFS). The concordance index, receiver operating characteristic curves, calibration curves, and decision curve analysis were used to evaluate the nomograms. A cohort composed of 50 patients who received radiotherapy or chemoradiotherapy (RT/CRT) alone was applied for generality testing of PIV and nomograms.
Patients with higher PIV (≥123.3) experienced a worse DFS (HR, 5.01; 95% CI, 3.25-7.72; <0.0001) and overall survival (OS) (HR, 5.23; 95% CI, 3.34-8.18; <0.0001) compared to patients with lower PIV (<123.3) in the development cohort. Predictors of Model A included age, TNM stage, neutrophil-to-lymphocyte ratio (NLR), and PIV, and that of Model B included TNM stage, lymphocyte-to-monocyte ratio (LMR), and PIV. In comparison with TNM stage alone, the two nomograms demonstrated good calibration and discrimination and showed satisfactory clinical utility in internal validation. The generality testing results showed that higher PIV was also associated with worse survival outcomes in the RT/CRT cohort and the possibility that the two nomograms may have a universal applicability for patients with different treatments.
The nomograms based on PIV, a simple but useful indicator, can provide prognosis prediction of individual HNSCC patients after radical surgery and may be broadly applicated for patients after RT/CRT alone.
有效的生物标志物——全免疫炎症值(PIV)对头颈部鳞状细胞癌(HNSCC)患者根治性手术或放化疗后的预后价值尚未得到充分研究。本研究旨在构建并验证基于PIV的列线图,以预测HNSCC患者的生存结局。
回顾性纳入161例行根治性手术的HNSCC患者作为开发队列。使用最大选择秩统计方法确定PIV的临界值。进行多变量Cox回归和最小绝对收缩和选择算子(LASSO)回归分析,以构建两个预测无病生存期(DFS)的列线图(模型A和模型B)。采用一致性指数、受试者工作特征曲线、校准曲线和决策曲线分析来评估列线图。一个由50例单纯接受放疗或放化疗(RT/CRT)的患者组成的队列用于PIV和列线图的通用性测试。
在开发队列中,与PIV较低(<123.3)的患者相比,PIV较高(≥123.3)的患者DFS更差(HR,5.01;95%CI,3.25 - 7.72;<0.0001),总生存期(OS)也更差(HR,5.23;95%CI,3.34 - 8.18;<0.0001)。模型A的预测因子包括年龄、TNM分期、中性粒细胞与淋巴细胞比值(NLR)和PIV,模型B的预测因子包括TNM分期、淋巴细胞与单核细胞比值(LMR)和PIV。与单独的TNM分期相比,这两个列线图显示出良好的校准和区分能力,并且在内部验证中显示出令人满意的临床实用性。通用性测试结果表明,在RT/CRT队列中,较高的PIV也与较差的生存结局相关,并且这两个列线图可能对不同治疗的患者具有普遍适用性。
基于PIV的列线图是一个简单但有用的指标,可以为HNSCC患者根治性手术后的个体预后提供预测,并且可能广泛应用于单纯接受RT/CRT后的患者。